Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syndrome: study design of a double-blind randomised controlled trial

Yan Li, Hongying Kuang, Wenjuan Shen, Hongli Ma, Yuehui Zhang, Elisabet Stener-Victorin, Ernest Hung, Yu Ng, Jianping Liu, Haixue Kuang, Lihui Hou, Xiaoke Wu, Yan Li, Hongying Kuang, Wenjuan Shen, Hongli Ma, Yuehui Zhang, Elisabet Stener-Victorin, Ernest Hung, Yu Ng, Jianping Liu, Haixue Kuang, Lihui Hou, Xiaoke Wu

Abstract

Introduction: Letrozole is being used as an alternative to clomiphene citrate in women with polycystic ovary syndrome (PCOS) requiring ovulation induction. Berberine, a major active component of Chinese herbal medicine rhizoma coptidis, has been used to improve insulin resistance to facilitate ovulation induction in women with PCOS but there is no study reporting the live birth or its potential as a complementary treatment to letrozole. We aim to determine the efficacy of letrozole with or without berberine in achieving live births among 660 infertile women with PCOS in Mainland China.

Methods and analysis: This study is a multicentre randomised, double-blind trial. The randomisation scheme is coordinated through the central mechanism and stratified by the participating site. Participants are randomised into one of the three treatment arms: (1) letrozole and berberine, (2) letrozole and berberine placebo, or (3) letrozole placebo and berberine. Berberine is administered three times a day (1.5 g/day) for up to 24 weeks, starting on day 1 after a spontaneous period or a withdrawal bleeding. Either letrozole or letrozole placebo 2.5 mg is given daily from day 3 to day 7 of the first three cycles and the dose is increased to 5 mg/day in the last three cycles, if not pregnant. The primary hypothesis is that the combination of berberine and letrozole results in a significantly higher live birth rate than letrozole or berberine alone.

Ethics and dissemination: The study was approved by the ethics committee of the First Affiliated Hospital of Heilongjiang University of Chinese Medicine. Study findings will be disseminated through peer-reviewed publications and conference presentations.

Trial registration: ClinicalTrials.gov identifier: NCT01116167.

Keywords: REPRODUCTIVE MEDICINE.

References

    1. Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet 2007;370:685–97
    1. Pauli JM, Raja-Khan N, Wu X, et al. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med 2011;28:1445–54
    1. Dickey RP, Taylor SN, Curole DN, et al. Incidence of spontaneous abortion in clomiphene pregnancies. Hum Reprod 1996;11:2623–8
    1. Gorlitsky GA, Kase NG, Speroff L. Ovulation and pregnancy rates with clomiphene citrate. Obstet Gynecol 1978;51:265–9
    1. Gysler M, March CM, Mishell DR, Jr, et al. A decade's experience with an individualized clomiphene treatment regimen including its effects on the postcoital test. Fertil Steril 1982;37:161–7
    1. Legro RS, Barnhart HX, Schlaff WD, et al. Cooperative Multicenter Reproductive Medicine Network Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551–66
    1. Gonen Y, Casper RF. Sonographic determination of an adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 1990;5:670–4
    1. Mitwally MF, Casper RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod Technol 2000;10:244–7
    1. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75:305–9
    1. He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reprod Biomed Online 2011;23:91–6
    1. Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Hum Reprod Update 2012;18:301–12
    1. Nahid L, Sirous K. Comparison of the effects of letrozole and clomiphene citrate for ovulation induction in infertile women with polycystic ovary syndrome. Minerva Ginecol 2012;6:253–8
    1. Legro RS, Kunselman AR, Brzyski RG, et al. ; NICHD Reproductive Medicine Network The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemp Clin Trials 2012;33:470–81
    1. Diamond MP, Mitwally M, Casper R, et al. ; NICHD Cooperative Reproductive Medicine Network Estimating rates of multiple gestation pregnancies: sample size calculation from the Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) trial. Contemp Clin Trials 2011;32:902–8
    1. Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012;5:CD003053.
    1. Sinawat S, Buppasiri P, Lumbiganon P, et al. Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. Cochrane Database Syst Rev 2012;1:CD006226
    1. Zhang J, Li T, Zhou L, et al. Chinese herbal medicine for subfertile women with polycystic ovarian syndrome. Cochrane Database Syst Rev 2010;9:CD007535.
    1. Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev 1997;2:94–103
    1. Dong H, Wang N, Zhao L, et al. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med 2012;2012:591654.
    1. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344–51
    1. Wu X. Theca insulin resistance: dexamethasone induction and berberine intervention. Fertil Steril 2010;94:s197
    1. Zhao L, Li W, Han F, et al. Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Fertil Steril 2011;95:461–3
    1. Gao L, Li W, Kuang HY. Of berberine and puerarin on dexamethasone-induced insulin resistance in porcine ovarian thecal cells. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009;29:623–7
    1. Wu XK, Yao JP, Hou LH, et al. Berberine improves insulin resistance in granulosa cells in a similar way to metformin. Fertil Steril 2006;86:459–60
    1. Wang XX, Li W, Liu YC. Controlling effect of berberine on in vitro synthesis and metabolism of steroid hormones in insulin resistant ovary. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010;30:161–6
    1. Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol 2012;166:99–105
    1. Jiang M, Lu C, Zhang C, et al. Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol 2012;140:634–42
    1. Hou LH, Wang YT, Wu XK. Today's gynecology of Chinese medicine. 1st edn People's Medical Publishing House, 2011, ISBN 978-7-117-13644-0/R.13645
    1. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008;23:462–77
    1. Liu JP. Clinical research methodology for evidence-based Chinese medicine. People's Medicine Publishing House, 2006; ISBN:9787117074193

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi